Understanding RPS2P17: A Potential Drug Target and Biomarker (G400963)

Target Name: RPS2P17

NCBI ID: G400963

RPS2P17

Other Name(s): ribosomal protein S2 pseudogene 17 | RPS2_6_247 | Ribosomal protein S2 pseudogene 17

Understanding RPS2P17: A Potential Drug Target and Biomarker

Ribosomal protein S2 pseudogene 17 (RPS2P17) is a protein that is expressed in various cell types of the human body, including muscle cells, heart cells, and brain cells. It is a key component of the ribosome, which is the protein machine that synthesizes proteins in the cell.

RPS2P17 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns make it an attractive target for researchers to study and develop new treatments.

One of the key reasons why RPS2P17 has been identified as a potential drug target is its role in the development and progression of cancer. RPS2P17 has been shown to be overexpressed in various types of cancer, including breast cancer, lung cancer, and colorectal cancer. Studies have also shown that high levels of RPS2P17 are associated with poor prognosis in cancer patients.

Another potential drug target for RPS2P17 is its role in neurodegenerative diseases. RPS2P17 has been shown to be expressed in the brains of individuals with Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. It has also been shown to be involved in the development of neurodegenerate diseases, such as Huntington's disease and motor neuron disease.

In addition to its potential as a drug target, RPS2P17 has also been identified as a potential biomarker for various diseases. Its expression has been shown to be associated with a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It has also has been shown to be a useful biomarker for tracking the effectiveness of certain treatments.

One of the challenges in studying RPS2P17 as a potential drug target is its complex structure. RPS2P17 is a cytoplasmic protein that is expressed in various cell types of the human body. It has a molecular weight of approximately 180 kDa and consists of a protein core and a cytoplasmic tail.

The protein core of RPS2P17 is composed of two distinct regions: an N-terminus and a C-terminus. The N-terminus is the region that is involved in protein-protein interactions and is known as the N-terminal domain. terminus is the region that is involved in the cell's signaling pathway and is known as the C-terminal domain.

Research has shown that the N-terminus of RPS2P17 is rich in conserved amino acid sequences, which are important for protein-protein interactions. The C-terminus of RPS2P17 is also rich in conservatory amino acid sequences, which are important for the cell's signaling pathway.

Another challenge in studying RPS2P17 as a potential drug target is its diverse expression patterns. RPS2P17 is expressed in a wide variety of cell types, including muscle cells, heart cells, and brain cells. It has been shown to be involved in a number of different cellular processes, including cell signaling, protein synthesis, and cell division.

This complexity makes it difficult to study RPS2P17 as a potential drug target. However, research has shown that targeting RPS2P17 using small molecules or antibodies can be effective in inhibiting its activity and reducing the growth of cancer cells.

In conclusion, RPS2P17 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and expression patterns make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand its role in the development and progression of cancer and neurodegenerative diseases, as well as its potential as a biomarker for these diseases.

Protein Name: Ribosomal Protein S2 Pseudogene 17

The "RPS2P17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS2P17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets